2020 Data: Current Insights from the T1D Exchange Registry
The T1D Exchange Registry launched last year, and it’s begun to provide a fascinating and vital look into some of the more detailed aspects of life with type 1 diabetes. From your age of diagnosis to frequency of testing, we’ve learned more about how you’re living, working, and caring for diabetes across the country.
Are Diabetes Alert Dogs Worth the Investment?
Recent studies have re-opened the long-running conversation about the cost-effectiveness and benefits of diabetes safety alert dogs.
At up to $25,000 – how useful are they?
Securing Patient Data: T1D Exchange and National Data Privacy Day
Today, January 28th, has been designated by the Council of Europe as Data Privacy and Protection Day since 2007, and recognized two years later by the U.S. Congress in 2009.
Pharma and Medtech CEOs at JPMorgan 2020 Weigh in on Insulin Pricing, Supply Issues, and Innovation
Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.
Tandem CCO Brian Hansen Discusses FDA Approval for Control IQ Algorithm with t:slim X2
Last month, the FDA approved the Tandem Diabetes Care update to its t:slim X2 insulin pump Control-IQ technology, clearing the way for the first automated and interoperable insulin dosing system on the U.S. market.
FDA Approves Fiasp Ultra-Fast Acting Insulin for Children with Type 1 Diabetes
The U.S. Food and Drug Administration has approved Novo Nordisk’s fast-acting Fiasp insulin for use in children as well as adults, the pharmaceutical firm announced Monday.
